Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses
Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses
NEW YORK, Nov. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Qfin Holdings, Inc. (NASDAQ: QFIN) between March 18, 2026 and August 25, 2026, inclusive (the “Class Period”), of the important November 30, 2026 lead plaintiff deadline.
NEW YORK, Nov. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Webull Corporation (NASDAQ: BULL) between April 26, 2025 and October 6, 2026, both dates inclusive (the “Class Period”), of the important December 7, 2026 lead plaintiff deadline in the securities class action…
NEW YORK, Nov. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of UP Fintech Holding Limited (NASDAQ: TIGR) between April 22, 2024 and June 2, 2026, both dates inclusive (the “Class Period”), of the important December 28, 2026 lead plaintiff deadline in the securities…
– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from Launch-HTN baseline –
